

Peer Review File

Article Information: <https://dx.doi.org/10.21037/atm-23-1854>

Reviewer A

Comment 1: The authors describe in detail the recent advances in immunotherapy in non-small cell lung cancer after publishing the article entitled "Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review". This paper is worthy enough to be accepted.

Reply 1: Many thanks to the reviewer for his comment. We are very honoured that our publication is to your liking and could in your view be published in the journal.

Reviewer B

This is a letter to the editor, to show an update on studies investigating the use of immunotherapy in NSCLC.

Comments:

Comment 1: Please change the first sentence, due to incorrect use of language. For example: Recently, the article entitled "Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review" was published. This systematic review gave an overview of studies investigating the use of immunotherapy in non-small cell lung cancer (NSCLC).

Reply 1: First of all, we would like to thank the reviewer for his comments. All these changes will undoubtedly improve the quality of the article. In the case of this first comment, you can see in lines 33-34 how the use of language has been changed for better comprehension.

Change in the text: lines 33-34.

Comment 2: Same goes for the second sentence. Please change, for example to: "Immunotherapy is currently the mainstay of treatment of NSCLC and researchers are constantly looking into new therapies"

Reply 2: As in the previous comment, a change has been made to the meaning of the sentence to make it easier to understand.

Change in the text: lines 35-38.

Comment 3: Line 57, add "for" : approval in November 2022 FOR the combination of platinum-doublet chemotherapy with

Reply 3: "FOR" has been added to the text.

Change in the text: lines 56-59.